InMed Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Detailed Sustainability assessment of InMed Pharmaceuticals Inc are reached by logging in. This webpage is a free Environmental, Social and Governance analysis covering InMed Pharmaceuticals Inc. Browse to the end of this webpage for potential risks for InMed Pharmaceuticals Inc based on industry, location and size.
InMed Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 0.0, social score of 8.0 and governance score of 8.0.
5.3
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
645 | Biomm SA | 5.4 | High |
645 | Tiziana Life Sciences PLC | 5.4 | High |
658 | InMed Pharmaceuticals Inc | 5.3 | High |
658 | Cellmid Ltd | 5.3 | High |
658 | Bio-Techne Corp | 5.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does InMed Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does InMed Pharmaceuticals Inc disclose current and historical energy intensity?
Does InMed Pharmaceuticals Inc report the average age of the workforce?
Does InMed Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does InMed Pharmaceuticals Inc disclose its ethnicity pay gap?
Does InMed Pharmaceuticals Inc disclose cybersecurity risks?
Does InMed Pharmaceuticals Inc offer flexible work?
Does InMed Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does InMed Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does InMed Pharmaceuticals Inc conduct supply chain audits?
Does InMed Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does InMed Pharmaceuticals Inc conduct 360 degree staff reviews?
Does InMed Pharmaceuticals Inc disclose the individual responsible for D&I?
Does InMed Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does InMed Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does InMed Pharmaceuticals Inc disclose water use targets?
Does InMed Pharmaceuticals Inc have careers partnerships with academic institutions?
Did InMed Pharmaceuticals Inc have a product recall in the last two years?
Does InMed Pharmaceuticals Inc disclose incidents of discrimination?
Does InMed Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has InMed Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does InMed Pharmaceuticals Inc disclose parental leave metrics?
Does InMed Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does InMed Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does InMed Pharmaceuticals Inc disclose the pay ratio of women to men?
Does InMed Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does InMed Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does InMed Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is InMed Pharmaceuticals Inc involved in embryonic stem cell research?
Does InMed Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does InMed Pharmaceuticals Inc disclose its waste policy?
Does InMed Pharmaceuticals Inc report according to TCFD requirements?
Does InMed Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does InMed Pharmaceuticals Inc disclose energy use targets?
Does InMed Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does InMed Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for InMed Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.